Inhibitor

Bibliography

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Inhibitor Report for: Gosogliptin

Gosogliptin (SatRx) was developed by Pfizer. It is approved for use in Russia


General
Type Drug, Piperidine, Pyrimidine, Gliptin
Chemical_Nomenclature (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone
Canonical SMILES C1CN(CC1(F)F)C(=O)C2CC(CN2)N3CCN(CC3)C4=NC=CC=N4
InChI InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
InChIKey QWEWGXUTRTXFRF-KBPBESRZSA-N
Other name(s) UNII-GI718UO477 ; PF-00734200 ; PF-734200 ; CHEMBL515387
________________________________________________________________________________________________
MW|366.41
Formula|C17H24F2N6O
CAS_number|869490-23-3
PubChem|11516136
UniChem|QWEWGXUTRTXFRF-KBPBESRZSA-N
IUPHAR|
Wikipedia|Gosogliptin

Target
Families | Gosogliptin ligand of proteins in family: DPP4N_Peptidase_S9
Stucture | 1 structure: 3F8S: Crystal structure of dipeptidyl peptidase IV in complex with inhibitor
Protein | human-DPP4

References:
Search PubMed for references concerning: Gosogliptin
    Title: The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency
    Dai H, Johnson SL, Terra SG, Marbury TC, Smith WB, Alcorn H, Boyd RA, Wang R, Nguyen TT
    Ref: British Journal of Clinical Pharmacology, 72:85, 2011 : PubMed

            

    Title: (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrr olidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor
    Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK and Piotrowski DW <8 more author(s)>
    Ref: Bioorganic & Medicinal Chemistry Lett, 19:1991, 2009 : PubMed